title: The relationship between clinical signs and hypercoagulable state in toxemia of pregnancy.
abstract: The hypercoagulable state in patients with toxemia of pregnancy was investigated in comparison with normal pregnant women using new coagulation parameters, mainly thrombin-antithrombin III (TAT) complexes, alpha 2-antiplasmin-plasmin complexes (PIP), and D-dimer FDP. When the patients were categorized by the classification of the WHO Study Group (1985), significant increases of TAT complexes and alpha 2-PIP complexes with decreases of the ATIII level were observed in the groups with preeclampsia and severe gestational hypertensive disease as compared to normal pregnant women. A significant increase of D-dimer FDP was observed in a group with severe gestational hypertensive disease. Additionally, the relationship between clinical signs and the hypercoagulable state in the patients was analyzed using canonical correlation analysis as a multivariate analysis. The clinical signs and coagulation parameters had a significantly high correlation of lambda 1 = 0.7219, p less than 0.01. The results showed that clinical signs were associated with simultaneous coagulation abnormalities. The indices obtained from the results of canonical correlation analysis, which were called the clinical index and the coagulation index, should be useful in evaluating the efficacy of anticoagulation therapy.
authors.affiliation: Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Terao
authors.forename: M
authors.initials: M
authors.lastname: Maki
authors.forename: T
authors.initials: T
authors.lastname: Ikenoue
authors.forename: K
authors.initials: K
authors.lastname: Gotoh
authors.forename: M
authors.initials: M
authors.lastname: Murata
authors.forename: H
authors.initials: H
authors.lastname: Iwasaki
authors.forename: J
authors.initials: J
authors.lastname: Shibata
authors.forename: M
authors.initials: M
authors.lastname: Nakabayashi
authors.forename: M
authors.initials: M
authors.lastname: Muraoka
authors.forename: Y
authors.initials: Y
authors.lastname: Takeda
mesh_terms: D000328:Adult; D000933:Antifibrinolytic Agents / Q000032:analysis; D000990:Antithrombin III / Q000032:analysis / Q000627:therapeutic use; D001777:Blood Coagulation / Q000502:physiology; D001778:Blood Coagulation Disorders / Q000175:diagnosis* / Q000188:drug therapy; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005341:Fibrinolysin / Q000032:analysis; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D010447:Peptide Hydrolases / Q000032:analysis; D011225:Pre-Eclampsia / Q000097:blood* / Q000188:drug therapy; D011247:Pregnancy; D000979:alpha-2-Antiplasmin
chemical_list: D000933:Antifibrinolytic Agents; D005338:Fibrin Fibrinogen Degradation Products; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D006493:Heparin; D010447:Peptide Hydrolases; D005341:Fibrinolysin